Today for Veteran's Day, we discuss the NRG Veteran Affairs and Military Treatment Facility Subcommittee and NCTN trials in the VA system with Subcommittee Chair, Dr. Vlad Sandulache.
For Pancreatic Cancer Awareness Month, we discuss the recently activated NRG-GI011 "LAP100" study for locally advanced pancreas cancer with study PI, Dr. Sanford.
Drs. Chun and Henke interview NRG NCORP PI, Dr. Deborah Bruner on the ins-and-outs of the NCI National Community Oncology Research Program (NCORP) as well as her trailblazing career thus far.
This episode, our co-hosts discuss the ASTRO late-breaking abstracts that were reported at the ASTRO 2025 annual meeting. Dr. Movsas discusses the quality of life results of NRG-LU005 and Dr. Mehta discusses the proton arm of NRG-BN001. Dr. Steven Frank takes a deeper look at proton implications through the NRG results that were presented at ASTRO.
PLEASE NOTE: There is a correction to Dr. Movsas’ institution as mentioned in the podcast in error. Dr. Movsas’ institution is Henry Ford Health.
NRG Oncology Podcast co-hosts sit with ASTRO President, Dr. Sameer Keole as well as ASTRO Plenary NRG research presenters, Dr. Shannon MacDonald (RadComp) and Dr. Rodney Ellis (NRG-GU005) to discuss results that were reported.
Our co-hosts discuss NRG-GU006 with Dr. Daniel Spratt. The results of NRG-GU006, a phase II clinical study in recurrent prostate cancer, were presented as a part of the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting Clinical Trials Session.
Our co-hosts sit with Dr. El-Deiry for his take on the current state of precision oncology, clinical research, and industry collaborations.
We interview Dr. Steven Waggoner on the NRG Oncology Ancillary Projects Committee (APC) and the conduct of ancillary projects.
We interview Dr. Erin Gillespie, PI of the NRG-CC014 "PREEMPT" study comparing radiation therapy to usual therapy for patients with high-risk bone metastases that are not causing pain.
We interview NRG Deputy Director of Membership and Research Integrity, Dr. David Miller, on the ins-and-outs of NRG Membership and the NRG Membership Committee.
We interview Dr. Jeff Bradley, the now Immediate Past Chair of the NRG Lung Cancer Committee regarding the past, present, and future of lung cancer in NRG as well as the importance of mentorship for our future research.
Dr. Ted Hong discusses the NRG-GI003 study comparing proton versus photons for hepatocellular carcinoma.
NRG Oncology Podcast Co-hosts sit with Dr. Edward Tanner, the Principal Investigator of the NRG-CC010 trial assessing the impact of sentinel lymph node mapping on patient-reported lower extremity limb dysfunction in endometrial cancer.
We discuss the results of NRG-NSABP B-51/RTOG 1304 in breast cancer, reported today in the New England Journal of Medicine.
Our co-hosts discuss triple-negative breast cancer in light of the recently presented results at the 2025 ASCO Annual Meeting. We interview Dr. Vicente Valero, the NRG-BR003 PI, and Dr. Julie Gralow, the Chief Medical Officer of ASCO about these findings and current research in breast cancer.
The NRG Oncology Podcast Co-hosts sit with NRG Oncology Patient Advocate, Tambre Leighn, to discuss what our patient advocates do in the process of our clinical trials from concept to reporting results. Tambre dives into the benefits of a great patient-physician relationship in building stronger trials as well as the need to tailor our trials around our patients' needs. Tambre also talks about the specific training advocates are encouraged to go through to help learn more about the clinical research process.
NRG Oncology Podcast co-hosts talk with Dr. Vinai Gondi, the Principal Investigator of the NRG-CC009 phase III clinical study assessing stereotactic radiosurgery (SRS) versus hippocampal-avoidant whole brain radiotherapy (HA-WBRT) for patients who have brain metastases (or cancer that has spread to the brain) from their small cell lung cancer (SCLC).
Our co-hosts sit with Drs. Ross Abrams and Karyn Goodman to discuss the results of NRG-RTOG 0848 studying adjuvant chemotherapy with or without chemoradiation for patients with resected periampullary pancreatic adenocarcinoma.
The NRG Oncology Podcast Co-hosts interview Dr. Clifford Hudis - the CEO of the American Society of Clinical Oncology (ASCO) on how ASCO and the NCTN collaborate, the cost and complexity of conducting research, as well as how to take action and advocate for research.
Our co-hosts discuss the currently active & accruing NRG-GI008 study, also known as the "CIRCULATE-NORTH AMERICA" study. This study will evaluate what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.